The company's strong cash position and revenue generation from Ryoncil provide runway for its clinical programs. The upcoming milestones in adult SR-aGvHD and CLBP could be significant value drivers. Investors should monitor progress in these trials and potential regulatory interactions.
Price Chart
Executive Summary
Mesoblast hosted an R&D Day event highlighting commercial progress of its FDA-approved product Ryoncil and upcoming milestones for its late-stage clinical pipeline. The company reported net revenue approaching $100M since Ryoncil's launch and announced key trial timelines for its chronic back pain and heart failure programs.
Key Facts
- Ryoncil net revenue approaching $100M since launch
- Adult SR-aGvHD Phase 3 trial initiated with BMT-CTN network
- FDA cleared IND for Ryoncil in Duchenne Muscular Dystrophy
- Enrollment completion expected for CLBP Phase 3 trial by end of April 2026
- Top-line results expected mid-2027 for CLBP trial
- Cash balance of $130M at December 31, 2025
- New term loan of $125M replaces existing higher-cost debt
Financial Impact
Net revenue approaching $100M since launch; $130M cash balance; $125M new term loan
Risk Factors
- Clinical trial failures in adult SR-aGvHD or CLBP programs
- Regulatory delays in approval pathways
- Competition in the allogeneic cell therapy space
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000045 |
| Exhibit: exhibit991rddaypresentat.htm | 0001345099-26-000045 |
| Document: form6-kxpressreleasecoverf.htm | 0001345099-26-000045 |
| Document: 0001345099-26-000045-index-headers.html | 0001345099-26-000045 |
| Document: 0001345099-26-000045-index.html | 0001345099-26-000045 |
| Document: 0001345099-26-000045.txt | 0001345099-26-000045 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 19w ago | 6-K | $1.55 $1.55 | · 0.00% | ▼ −3.89% | $1.32 (−14.84%) |
Apr 30, 2026 25w ago | 6-K | $1.70 $1.70 | · 0.00% | ▼ −5.23% | $1.32 (−22.35%) |
Apr 16, 2026 27w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▲ +0.88% | $1.32 (−17.50%) |
Apr 15, 2026 27w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▲ +0.21% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers